Vitro Biopharma Inc

Vitro Biopharma, Inc. develops and commercializes regenerative medicine and cellular therapy, targeting autoimmune diseases and inflammatory disorders. The company provides stem cell technology, patent portfolio and proprietary technology and cell lines for applications in autoimmune disorders and inflammatory disease processes and stem cell research. Its products include native mesenchymal stem cells, several lines of Cancer-Associated Fibroblasts and native fibroblasts that are used by these institutions for stem cell research and the development of advanced immunotherapy of cancer. The company was founded by James R. Musick on March 31, 1986 and is headquartered in Denver, CO.

Vitro Biopharma, Inc. has filed for a $10 million IPO to develop stem cell-based treatments for Pitt-Hopkins syndrome and long COVID. The company is at a preclinical stage of development, making the IPO highly risky. My opinion on the Vitro Biopharma, Inc. IPO is to Avoid it [Sell].

News for Vitro Biopharma Inc Stock (VTRO)